10-Q: Invizyne Technologies Reports Q3 2024 Results, Highlights IPO and Growth Initiatives

Invizyne Technologies reported its Q3 2024 financial results, noting increased operating costs and a net loss, while also highlighting its recent IPO and future growth plans.

Summary

• Invizyne Technologies, a pre-revenue biotechnology company, reported a net loss of $1.66 million for the three months ended September 30, 2024, and a net loss of $4.03 million for the nine months ended September 30, 2024.
• The company's operating costs increased significantly, with general and administrative costs rising to $888,239 for the quarter and $2.71 million for the nine months, and research and development costs, net of grants, reaching $723,487 for the quarter and $1.24 million for the nine months.
• The company completed its IPO on November 13, 2024, raising approximately $14.3 million in net proceeds.
• The company plans to use the IPO proceeds for expansion of production capabilities, staffing, R&D, and repayment of intercompany loans.
• As of September 30, 2024, the company had cash and cash equivalents of $233,935 and a working capital deficit of $4.38 million.
• The company has received grants from the Department of Energy and the NIH, with the Department of Energy contributing 64% and the NIH contributing 36% of grant reimbursements for the nine months ended September 30, 2024.
• The company has a license agreement with The Regents of the University of California, requiring milestone payments upon reaching certain sales thresholds.
• The company has two operating leases for office space, with a weighted average remaining lease term of 5.20 years and a weighted average discount rate of 7.88%.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the successful IPO is a positive development, the significant net losses, increasing operating costs, and working capital deficit raise concerns. The company's future success hinges on its ability to effectively utilize the IPO proceeds and achieve commercial viability.

Positives

• The successful completion of the IPO provides the company with significant capital to fund its growth initiatives.
• The company secured a $1 million cost share grant from the Department of Defense (DOD) BioMADE initiative.
• The company has a differentiated and unique synthetic biology platform.
• The company has a license agreement with The Regents of the University of California for its technology.
• The company has received grants from the Department of Energy and the NIH.

Negatives

• The company reported a significant net loss of $1.66 million for the quarter and $4.03 million for the nine months ended September 30, 2024.
• The company's operating costs have increased substantially, particularly in general and administrative expenses.
• The company has a working capital deficit of $4.38 million as of September 30, 2024.
• The company is a pre-revenue development stage company.
• The company's financial statements indicate a going concern issue without additional financial support.

Risks

• The company's ability to continue as a going concern is dependent on continued financial support, raising equity or debt financing, and achieving profitable operations.
• The company's technology may not achieve commercial viability or gain market acceptance.
• The company is subject to risks associated with the development of new technologies and regulatory approvals.
• The company is exposed to potential economic recession and its impact on the general business environment and capital markets.
• The company has material weaknesses in internal control over financial reporting.

Future Outlook

The company plans to use the IPO proceeds for expansion of production capabilities, staffing, R&D, and repayment of intercompany loans. The company also intends to pursue additional grants to improve its working capital position. The company believes it will not need to raise capital in the immediate future based on its working capital after the IPO and its program of seeking various grants.

Management Comments

• Management believes that Invizyne's technology is a differentiated and unique synthetic biology platform.
• Management believes the platform will enable scalable production of chemical molecules found in nature.
• Management believes the platform will be more environmentally friendly and sustainable than typical methods used today.
• Management believes the platform could significantly change biomanufacturing through leveraging cell-free, multi-step enzyme-based systems.
• Management considers the grants receivable to be fully collectable due to the historical experience with the Federal Government of the United States of America.

Industry Context

Invizyne operates in the biotechnology sector, specifically focusing on synthetic biology. This sector is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. The company's focus on cell-free biomanufacturing aligns with the industry's trend towards more sustainable and efficient production methods. The company's IPO and subsequent funding will allow it to compete with other companies in the space.

Comparison to Industry Standards

• Invizyne's financial performance is typical of a pre-revenue, development-stage biotechnology company, with significant operating losses and reliance on grants and equity financing.
• Compared to other synthetic biology companies, Invizyne's focus on cell-free systems is a differentiating factor, potentially offering advantages in scalability and sustainability.
• The company's reliance on government grants is common in the industry, but the ability to secure and manage these grants is a key factor for success.
• The company's IPO is a significant milestone, providing the necessary capital to advance its technology and compete with established players in the market.
• The company's operating losses are in line with other companies in the sector at a similar stage of development, but the ability to control costs and achieve profitability will be critical for long-term success.

Related Party Transactions

• MDB Capital Holdings, LLC has advanced $3,669,933 to the Company as of September 30, 2024.
• The related party loans are undocumented and amount to $3,345,000 as of September 30, 2024, and bears interest at a rate of 5%, compounding annually.
• The company intends to repay the full amount of the intercompany payables and all outstanding interest due in the aggregate amount of $77,066 as of September 30, 2024, promptly after the consummation of the initial public offering of Common Stock by the Company.
• On July 3, 2023, Invizyne executed a simple agreement for future equity (SAFE) with MDB Capital Holdings LLC which provided funding of $785,000.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and the use of IPO proceeds.
• Employees will be impacted by the company's growth plans and potential for increased staffing.
• Customers and suppliers will be impacted by the company's ability to commercialize its technologies.
• Creditors will be impacted by the company's ability to repay its debts, including the intercompany loans from MDB Capital Holdings, LLC.

Next Steps

• The company will use the IPO proceeds to expand production capabilities, increase staffing, fund R&D, and repay intercompany loans.
• The company will continue to pursue additional grants to improve its working capital position.
• The company will focus on the development of its SimplePath synthetic biology platform.
• The company will work towards achieving commercialization of its technologies.

Key Dates

Keywords

biotechnology, synthetic biology, IPO, research and development, grants, financial results, operating costs, net loss, capital raise, biomanufacturing